SEC Inspector General Attributes Failure to Uncover Madoff Scheme to Agency Incompetence

In a nearly 500-page report, the Securities and Exchange Commission Inspector General H. David Kotz issued detailed findings on how the SEC failed to uncover Bernie Madoff’s colossal Ponzi scheme. In a nearly 500-page report, the Securities and Exchange Commission Inspector General H. David Kotz issued detailed findings on how the SEC failed to uncover […]

September 28, 2009

In a nearly 500-page report, the Securities and Exchange Commission Inspector General H. David Kotz issued detailed findings on how the SEC failed to uncover Bernie Madoff’s colossal Ponzi scheme.

In a nearly 500-page report, the Securities and Exchange Commission Inspector General H. David Kotz issued detailed findings on how the SEC failed to uncover Bernie Madoff’s colossal Ponzi scheme.  Kotz noted that the SEC had received six credible warnings about Madoff’s far-reaching fraud over 16 years, but failed each time to act and expose the scheme.  Disturbingly, Kotz further observed that despite three examinations and two investigations, “a thorough and competent investigation or examination was never performed.”

For the many thousands of Madoff victims, the report’s findings of incompetence offered little solace.  Indeed, it only confirmed in their minds what they already believed – that their reliance on the SEC to monitor and police broker-dealers was misplaced.  What was surprising, however, was the extent to which the Inspector General took to task the agency that he was tasked to examine.

You can download the full report (PDF 3.59 mb) from our website.

Stephen A. Weiss, founding partner of Seeger Weiss LLP, has been a leading advocate on behalf of Madoff victims and has been quoted in several news sources, including the New York Times, Bloomberg.com, Reuters, and FOREX Pro, about the claims of defrauded investors.  Watch him in Sky News’ coverage of the Madoff scheme below:

Since the Madoff revelations broke in December 2008, Mr. Weiss and his firm have occupied the forefront of the litigation against Madoff’s investment firm.  Seeger Weiss, along with co-counsel Milberg LLP, has been retained to represent nearly $1 billion in claims from defrauded shareholders around the world.  Madoff’s brand of deception, though similar to a pyramid scheme, proved far more insidious because it relied upon Madoff’s burnished reputation in the highly regulated investment community. Mr. Weiss, who began calling on members of Congress to impose strong regulatory reforms immediately following Madoff’s public admissions, believes that Kotz’s report provides damning evidence for the need for stronger and more effective government enforcement tools.

Related News

October 30, 2026
Seeger Weiss Named Litigation Department of the Year for Products Liability and Mass Torts at the 2026 New Jersey Legal Awards

New Jersey-based Seeger Weiss has been named Litigation Department of the Year in the Products Liability and Mass Torts category at the New Jersey Law Journal’s 2026 New Jersey Legal Awards. Winners were announced on October 29, 2026, at The Palace at Somerset Park in Somerset, New Jersey. Over the past year, the department took […]

Read More
October 25, 2026
Seeger Weiss Partner Christopher A. Seeger Receives Inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law

Seeger Weiss Partner Christopher Seeger received the inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law, his alma mater, at the school’s 50th Anniversary Gala at the Hall des Lumières in New York City on October 22, 2026. The award is named for Monroe Price, who served as Dean of Cardozo […]

Read More
October 23, 2026
Seeger Weiss’s Christopher A. Seeger Appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation

Seeger Weiss LLP is pleased to announce that Partner Christopher A. Seeger has been appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, pending in the U.S. District Court for the District of New Jersey. The litigation involves claims that Dupixent, an injectable biologic prescribed to treat inflammatory conditions including […]

Read More
↑